AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company with a market capitalisation of approximately $356 billion, known for blockbuster drugs like Humira, Skyrizi, and Rinvoq. For Muslim investors asking “is AbbVie ethical-trading/” style=”color:#D8AF44;text-decoration:underline” title=”Ethical Trading”>halal?”, the answer hinges on its financial structure rather than its core business. While pharmaceutical development is generally considered permissible, AbbVie’s heavy debt load creates a significant compliance obstacle.
What We Screen For
Shariah-compliant equity screening examines three core financial ratios:
- Debt Purity — Measures interest-bearing debt relative to market capitalisation. Higher scores indicate lower debt dependency.
- Liquidity Purity — Assesses whether a company’s assets are predominantly productive. Scores above 50% are preferred.
- Revenue Purity — Evaluates what share of revenue derives from permissible activities. Scores above 67% indicate compliance.
The Numbers
| Screening Ratio | AbbVie Score | Threshold | Status |
|---|---|---|---|
| Debt Purity | 0.00% | >50% | ✗ Fail |
| Liquidity Purity | 99.39% | >50% | ✓ Pass |
| Revenue Purity | 91.30% | >67% | ✓ Pass |
| Overall Ethical Score | 56.09% | — | Silver Tier |
Detailed Assessment
AbbVie’s Shariah compliance challenge is straightforward: the company carries too much interest-bearing debt. A debt purity score of 0.00% is a decisive failure. This stems from the massive borrowing AbbVie undertook to fund its $63 billion acquisition of Allergan in 2020 and subsequent acquisitions like Cerevel Therapeutics and ImmunoGen. As of the latest filings, AbbVie carries approximately $57 billion in long-term debt.
The other two screens paint a more favourable picture. Revenue purity at 91.30% is strong — AbbVie’s income comes overwhelmingly from pharmaceutical product sales, which is considered permissible under most scholarly opinions. Medicines that treat disease and improve quality of life are generally viewed as beneficial to society.
Liquidity purity at 99.39% is excellent, meaning nearly all of AbbVie’s assets are productive rather than interest-generating financial instruments. The company’s asset base consists primarily of intangible assets (drug patents and goodwill from acquisitions) and tangible manufacturing infrastructure.
Despite the strong revenue and liquidity metrics, the debt purity failure alone is sufficient to render AbbVie non-compliant under standard AAOIFI and most other Shariah screening methodologies. The overall ethical score of 56.09% and Silver Tier classification reflects a company that does good work but finances it through impermissible means.
Shariah-Compliant Alternatives in Healthcare
Investors seeking halal pharmaceutical exposure have options with stronger financial profiles:
- Johnson & Johnson (JNJ) — A diversified healthcare company with a more conservative balance sheet and strong purity ratios.
- Eli Lilly (LLY) — Silver Tier, 58.29% ethical score. Exceptional revenue purity at 100%, though debt purity remains a concern.
Explore the full list on our Ethical Trading Screener.
Further Research
View the full AbbVie profile on our ABBV Ticker Page.
Explore Shariah-screened equities on our Ethical Trading Screener.
Deepen Your Understanding
Related articles from the Titan Protect Foundry:
